Savara Announces New Employment Inducement Grant
Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focusing on rare respiratory diseases, has announced inducement awards for a new employee. The Compensation Committee granted these awards on August 15, 2024, consisting of:
1. Options to purchase 20,000 shares of common stock
2. Restricted stock units (RSUs) covering 20,000 shares of common stock
These equity awards were granted under the Savara Inc. 2021 Inducement Equity Incentive Plan. The options have an exercise price of $4.51 per share, vesting quarterly over four years. The RSUs vest fully after two years, subject to continued employment.
Savara Inc. (Nasdaq: SVRA), un'azienda biofarmaceutica in fase clinica che si concentra sulle malattie respiratorie rare, ha annunciato premi di indennizzo per un nuovo dipendente. Il Comitato per la Retribuzione ha concesso questi premi il 15 agosto 2024, consistenti in:
1. Opzioni per acquistare 20.000 azioni di azioni ordinarie
2. Unità d'azione vincolate (RSU) che coprono 20.000 azioni di azioni ordinarie
Questi premi azionari sono stati concessi nell'ambito del Piano di Incentivazione Azionaria per Inducimenti Savara Inc. 2021. Le opzioni hanno un prezzo di esercizio di 4,51 $ per azione, con maturazione trimestrale su un periodo di quattro anni. Le RSU maturano completamente dopo due anni, soggette a un'occupazione continuativa.
Savara Inc. (Nasdaq: SVRA), una compañía biofarmacéutica en etapa clínica centrada en enfermedades respiratorias raras, ha anunciado premios de inducción para un nuevo empleado. El Comité de Compensación otorgó estos premios el 15 de agosto de 2024, que consisten en:
1. Opciones para comprar 20,000 acciones de acciones ordinarias
2. Unidades de acciones restringidas (RSUs) que cubren 20,000 acciones de acciones ordinarias
Estos premios de capital se otorgaron bajo el Plan de Incentivos de Capital por Inducción de Savara Inc. 2021. Las opciones tienen un precio de ejercicio de $4.51 por acción, con adquisición trimestral durante cuatro años. Las RSUs se adquieren completamente después de dos años, sujetas a empleo continuo.
사바라 Inc. (Nasdaq: SVRA)는 희귀 호흡기 질환에 중점을 둔 임상 단계의 생명공학 회사로, 신규 직원에 대한 인센티브 보상을 발표했습니다. 보상 위원회는 2024년 8월 15일에 다음과 같은 보상을 승인했습니다:
1. 20,000주의 보통주를 구매할 수 있는 옵션
2. 20,000주의 보통주를 포함하는 제한 주식 단위(RSU)
이 주식 보상은 Savara Inc. 2021 인센티브 주식 계획에 따라 부여되었습니다. 옵션의 행사 가격은 주당 4.51달러이며, 4년 동안 분기마다 발생합니다. RSU는 연속 근무 조건으로 2년 후에 전액 확정됩니다.
Savara Inc. (Nasdaq: SVRA), une société biopharmaceutique en phase clinique spécialisée dans les maladies respiratoires rares, a annoncé des récompenses d'incitation pour un nouvel employé. Le Comité de Rémunération a accordé ces récompenses le 15 août 2024, comprenant :
1. Des options pour acheter 20 000 actions ordinaires
2. Des unités d'actions restreintes (RSU) couvrant 20 000 actions ordinaires
Ces récompenses en actions ont été accordées dans le cadre du Plan d'incitation en capital d'incitation 2021 de Savara Inc. Les options ont un prix d'exercice de 4,51 $ par action, avec une acquisition par tranche trimestrielle sur quatre ans. Les RSU deviennent entièrement viables après deux ans, sous réserve d'un emploi continu.
Savara Inc. (Nasdaq: SVRA), ein in der klinischen Phase tätiges biopharmazeutisches Unternehmen, das sich auf seltene Atemwegserkrankungen spezialisiert hat, hat Induktionsprämien für einen neuen Mitarbeiter bekannt gegeben. Der Vergütungsausschuss hat diese Prämien am 15. August 2024 gewährt, und sie bestehen aus:
1. Optionen zum Kauf von 20.000 Aktien des Stammkapitals
2. Eingeschränkte Aktieneinheiten (RSUs) für 20.000 Aktien des Stammkapitals
Diese Eigenkapitalprämien wurden im Rahmen des Savara Inc. 2021 Induktions-Eigenkapitalanreizplans gewährt. Die Optionen haben einen Ausübungspreis von 4,51 $ pro Aktie und vesten vierteljährlich über einen Zeitraum von vier Jahren. Die RSUs vesten vollständig nach zwei Jahren, vorbehaltlich einer fortdauernden Beschäftigung.
- Attracting new talent with equity incentives
- Aligning employee interests with company performance through stock options and RSUs
- Potential dilution of existing shareholders' equity
On August 15, 2024, the Compensation Committee of Savara's Board of Directors granted the inducement awards to a new employee who recently joined the Company. The inducement awards consist of options to purchase 20,000 shares of the Company’s common stock and restricted stock units (RSUs) covering 20,000 shares of the Company’s common stock. These equity awards were granted under the Savara Inc. 2021 Inducement Equity Incentive Plan pursuant to Rule 5635(c)(4) of the NASDAQ Listing Rules as an inducement material to the employee’s acceptance of employment with the Company.
The options have an exercise price of
About Savara
Savara is a clinical stage biopharmaceutical company focused on rare respiratory diseases. Our lead program, molgramostim nebulizer solution, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). Molgramostim is delivered via an investigational eFlow® Nebulizer System (PARI Pharma GmbH). Our management team has significant experience in rare respiratory diseases and pulmonary medicine, identifying unmet needs, and effectively advancing product candidates to approval and commercialization. More information can be found at www.savarapharma.com. (X, formerly known as Twitter: @SavaraPharma, LinkedIn: www.linkedin.com/company/savara-pharmaceuticals/).
View source version on businesswire.com: https://www.businesswire.com/news/home/20240816412116/en/
Savara Inc. IR & PR
Anne Erickson (anne.erickson@savarapharma.com)
(512) 851-1366
Source: Savara Inc.
FAQ
What inducement awards did Savara (SVRA) grant to a new employee on August 15, 2024?
What is the exercise price of the stock options granted by Savara (SVRA) in the recent inducement award?
How do the RSUs vest in Savara's (SVRA) recent inducement grant?
Under which plan were Savara's (SVRA) inducement awards granted?
